A109960 logo

AP Healthcare Stock Price

Symbol: KOSDAQ:A109960Market Cap: ₩69.3bCategory: Pharmaceuticals & Biotech

A109960 Share Price Performance

A109960 Community Fair Values

    Recent A109960 News & Updates

    No updates

    AP Healthcare Inc. Key Details

    ₩16.3b

    Revenue

    ₩10.9b

    Cost of Revenue

    ₩5.4b

    Gross Profit

    ₩82.1b

    Other Expenses

    -₩76.7b

    Earnings

    Last Reported Earnings
    Mar 31, 2025
    Next Reporting Earnings
    n/a
    Earnings per share (EPS)
    -347.48
    Gross Margin
    33.11%
    Net Profit Margin
    -469.42%
    Debt/Equity Ratio
    2.1%

    AP Healthcare Inc. Competitors

     
     
     
     
     
     
     
     
     
     
     
     

    About A109960

    Founded
    1998
    Employees
    12
    CEO
    n/a
    WebsiteView website
    www.aprogen-hng.com

    AP Healthcare Inc. distributes pharmaceutical products in South Korea. It offers prescription and over-the-counter medication, such as antibiotics, antifungal agent, antiviral drugs, infusion solution, peptic ulcer medication, osteoarthritis treatment, purifying solvent, brain function improvement agent, respiratory solvent, topical medicine, adrenocorticosteroids, urinary medicine, hair loss treatment, antipyretic analgesic and anti-inflammatory agent, antihistamines, obesity agents, neural contract, liver extract, fire extinguisher solvent, etc. The company was formerly known as Aprogen Healthcare & Games Inc. and changed its name to AP Healthcare Inc. in April 2024. AP Healthcare Inc. was founded in 1998 and is headquartered in Seongnam-si, South Korea.

    South Korean Market Performance

    • 7 Days: 1.5%
    • 3 Months: 24.6%
    • 1 Year: 13.5%
    • Year to Date: 32.5%
    The market is up 1.5% over the last week, with the Information Technology sector leading the way, up 5.3%. In the last year, the market has climbed 14%. Earnings are forecast to grow by 21% annually. Market details ›
    This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
    Continue reading